Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | PRCP | P42785 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517681 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP1A2CYP2D6KCNH2 | |
| SCHEMBL12159739 | 0.97 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP1A2CYP2D6KCNH2 | |
| SCHEMBL12175116 | 0.97 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP1A2CYP2D6KCNH2 | |
| SCHEMBL13635774 | 0.97 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP1A2CYP2D6KCNH2 | |
| SCHEMBL3343497 | 0.94 | CYP3A4 (0.76) | CYP3A4CYP2C9CYP1A2CYP2D6KCNH2 | |
| SCHEMBL3343491 | 0.94 | CYP3A4 (0.76) | CYP3A4CYP2C9CYP1A2CYP2D6KCNH2 | |
| SCHEMBL4517674 | 0.92 | CYP3A4 (0.60) | CYP3A4CYP2C9CYP1A2CYP2D6KCNH2 | |
| SCHEMBL1747645 | 0.92 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP1A2CYP2D6KCNH2 | |
| SCHEMBL1747644 | 0.92 | CYP3A4 (0.62) | CYP3A4CYP2C9CYP1A2CYP2D6KCNH2 | |
| SCHEMBL15482033 | 0.91 | CYP3A4 (0.80) | CYP3A4CYP2C9CYP1A2CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | claimed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | claimed |
| EP-2049522-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-05-14 | — | — | EP | claimed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | claimed |
| US-8900566-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2049522-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP3A4 1107/4885CYP2C9 2585/4885CYP1A2 2139/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | CYP3A4 1107/4885CYP2C9 2585/4885CYP1A2 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.